Current Headlines

  1. ADC Therapeutics And Freenome Enter Biomarker Development Collaboration
    8/26/2019

    ADC Therapeutics , an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw, recently announced that they have entered a biomarker development collaboration in which ADC Therapeutics will use Freenome’s platform to identify patients who are most likely to respond to treatment with ADCT-402 (loncastuximab tesirine)

  2. HotSpot Therapeutics Announces Acquisition Of Macroceutics, Inc.
    8/23/2019

    HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery of nature's regulatory sites to advance allosteric drug discovery, today announced the acquisition of Macroceutics, Inc., a provider of DNA-encoded library (DEL) screening technologies

  3. Voronoi Selects CDD Vault Platform To Manage Its Drug Discovery Data
    8/23/2019

    Voronoi, a drug discovery and development biotech company in Korea announced today that it has, after an extensive evaluation process, selected CDD Vault as its platform of choice to manage its drug discovery data and collaborative projects

  4. Researchers Advance Organ-On-Chip Technology To Advance Drug Development
    8/23/2019

    Researchers from Carnegie Mellon University (CMU) and Nanyang Technological University in Singapore have developed an organ-on-an-electronic-chip platform, which uses bioelectrical sensors to measure the electrophysiology of the heart cells in three dimensions

  5. Researchers Identify Key Areas Of Measles Virus Polymerase To Target For Antiviral Drug Development
    8/22/2019

    Targeting specific areas of the measles virus polymerase, a protein complex that copies the viral genome, can effectively fight the measles virus and be used as an approach to developing new antiviral drugs to treat the serious infectious disease, according to a study by the Institute for Biomedical Sciences at Georgia State University published in PLoS Pathogens

  6. Researchers Make Potential Breakthrough In Cancer Drug Development
    8/21/2019

    A Victoria University of Wellington research team has developed an exciting new lead in the search for cancer treatments, creating alternative versions in the laboratory of a rare natural compound that targets some types of cancer

  7. Innovent Enters A Licensing Agreement With Lilly To Develop & Commercialize A Novel Diabetes Medicine In China
    8/21/2019

    Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of oxyntomodulin analog, OXM3, in China

  8. CMAB And Kintor Announce A New Comprehensive Collaboration To Develop And Manufacture The ALK-1 Monoclonal Antibody
    8/21/2019

    CMAB Biopharma (Suzhou) Inc. ("CMAB"), a pure-play CDMO business in biologics and Suzhou Kintor Pharmaceuticals, Inc. ("Kintor"), an innovative biopharmaceutical enterprise, announced a comprehensive strategic cooperation agreement for the development and manufacturing of Kintor's ALK-1 mAb

  9. SHINKEI Therapeutics Announces Investigational New Drug Application Submission For MR-201, A Novel Dosage Form For Treatment Of Pseudobulbar Affect
    8/21/2019

    SHINKEI Therapeutics, a clinical stage pharmaceutical company focused on the development of drugs for the treatment of Central Nervous System (CNS) disorders, today announced the filing of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) of MR-201, a novel dosage form for the treatment of Pseudobulbar Affect (PBA)

  10. New Auto-Injector Pen Assembly Capabilities Compliment Fill-Finish Capabilities In North America And Europe
    8/20/2019

    Thermo Fisher recently expanded their steriles capabilities to support clients requiring auto-injector devices for patient self-administration.  Located in dedicated and flexible GMP-compliant cabins, Thermo Fisher can accommodate both small and multi-million unit runs. This further increases the company’s breadth of sterile services, which also includes cartridge and vial fill-finish, prefilled syringe assembly, primary and secondary packaging, and label services.